Robert Iannone Sells 2,403 Shares of Jazz Pharmaceuticals plc (NASDAQ:JAZZ) Stock

Jazz Pharmaceuticals plc (NASDAQ:JAZZ) CMO Robert Iannone sold 2,403 shares of the business’s stock in a transaction on Monday, March 10th. The stock was sold at an average price of $138.41, for a total transaction of $332,599.23. Following the completion of the sale, the chief marketing officer now directly owns 79,621 shares of the company’s stock, valued at approximately $11,020,342.61. The trade was a 2.93 % decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink.

Robert Iannone also recently made the following trade(s):

• On Friday, March 7th, Robert Iannone sold 7,080 shares of Jazz Pharmaceuticals stock. The shares were sold at an average price of $138.60, for a total transaction of $981,288.00.

Jazz Pharmaceuticals Trading Down 2.0 %

Shares of Jazz Pharmaceuticals stock traded down $2.70 during trading hours on Wednesday, hitting $134.16. The company’s stock had a trading volume of 766,031 shares, compared to its average volume of 771,293. The company has a debt-to-equity ratio of 1.46, a quick ratio of 3.74 and a current ratio of 4.26. The stock has a market cap of $8.15 billion, a price-to-earnings ratio of 18.90, a P/E/G ratio of 1.04 and a beta of 0.44. The firm has a fifty day moving average of $128.70 and a 200-day moving average of $120.40. Jazz Pharmaceuticals plc has a twelve month low of $99.06 and a twelve month high of $148.06.

Wall Street Analysts Forecast Growth

JAZZ has been the subject of several research reports. JPMorgan Chase & Co. boosted their price objective on Jazz Pharmaceuticals from $200.00 to $209.00 and gave the stock an “overweight” rating in a research note on Wednesday, February 26th. UBS Group upgraded Jazz Pharmaceuticals from a “neutral” rating to a “buy” rating and boosted their price target for the stock from $145.00 to $179.00 in a research report on Friday, March 7th. Wells Fargo & Company upgraded Jazz Pharmaceuticals from an “equal weight” rating to an “overweight” rating and raised their price objective for the company from $130.00 to $170.00 in a report on Thursday, February 13th. Cantor Fitzgerald lowered shares of Jazz Pharmaceuticals from an “overweight” rating to a “neutral” rating and upped their target price for the stock from $140.00 to $150.00 in a report on Wednesday, February 26th. Finally, Barclays reiterated an “overweight” rating and issued a $200.00 target price (up from $190.00) on shares of Jazz Pharmaceuticals in a research report on Thursday, February 27th. One research analyst has rated the stock with a hold rating, fourteen have assigned a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat, the stock has a consensus rating of “Buy” and a consensus target price of $190.53.

Hedge Funds Weigh In On Jazz Pharmaceuticals

A number of hedge funds have recently made changes to their positions in the stock. LSV Asset Management lifted its stake in Jazz Pharmaceuticals by 1.5% during the fourth quarter. LSV Asset Management now owns 2,531,050 shares of the specialty pharmaceutical company’s stock worth $311,699,000 after purchasing an additional 37,108 shares in the last quarter. Pacer Advisors Inc. lifted its stake in Jazz Pharmaceuticals by 5.5% during the 4th quarter. Pacer Advisors Inc. now owns 2,214,480 shares of the specialty pharmaceutical company’s stock worth $272,713,000 after acquiring an additional 115,102 shares in the last quarter. Dimensional Fund Advisors LP boosted its holdings in Jazz Pharmaceuticals by 18.7% during the 4th quarter. Dimensional Fund Advisors LP now owns 2,035,070 shares of the specialty pharmaceutical company’s stock valued at $250,619,000 after acquiring an additional 320,724 shares during the period. Capital World Investors boosted its holdings in Jazz Pharmaceuticals by 5.7% during the 4th quarter. Capital World Investors now owns 1,923,342 shares of the specialty pharmaceutical company’s stock valued at $236,860,000 after acquiring an additional 104,195 shares during the period. Finally, Ameriprise Financial Inc. grew its position in Jazz Pharmaceuticals by 20.9% in the 4th quarter. Ameriprise Financial Inc. now owns 1,827,658 shares of the specialty pharmaceutical company’s stock valued at $225,076,000 after acquiring an additional 315,608 shares in the last quarter. Hedge funds and other institutional investors own 89.14% of the company’s stock.

About Jazz Pharmaceuticals

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.